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Abstract
Individualized treatment rules (ITR) can improve health outcomes
by recognizing that patients may respond differently to treatment and
assigning therapy with the most desirable predicted outcome for each
individual. Flexible and efficient prediction models are desired as a ba-
sis for such ITRs to handle potentially complex interactions between
patient factors and treatment. Modern Bayesian semiparametric and
nonparametric regression models provide an attractive avenue in this
regard as these allow natural posterior uncertainty quantification of
patient specific treatment decisions as well as the population wide
value of the prediction-based ITR. In addition, via the use of such
models, inference is also available for the value of the Optimal ITR.
We propose such an approach and implement it using Bayesian Addi-
tive Regression Trees (BART) as this model has been shown to per-
form well in fitting nonparametric regression functions to continuous
and binary responses, even with many covariates. It is also compu-
tationally efficient for use in practice. With BART we investigate a
treatment strategy which utilizes individualized predictions of patient
outcomes from BART models. Posterior distributions of patient out-
comes under each treatment are used to assign the treatment that
maximizes the expected posterior utility. We also describe how to ap-
proximate such a treatment policy with a clinically interpretable ITR,
and quantify its expected outcome. The proposed method performs
very well in extensive simulation studies in comparison with several
existing methods. We illustrate the usage of the proposed method to
identify an individualized choice of conditioning regimen for patients
undergoing hematopoietic cell transplantation and quantify the value
of this method of choice in relation to the Optimal ITR as well as
non-individualized treatment strategies.
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1 Introduction
There is increasing recognition in clinical trials that patients are heteroge-
neous and may respond differently to treatment. A major goal of precision
medicine is to identify which patients respond best to which treatments and
tailor the treatment strategy to the individual patient. This personalization
of treatment based on patient clinical features, biomarkers, and genetic in-
formation is formalized as an individualized treatment rule (ITR) by Qian
and Murphy [15]. Individualized treatment rules extend classical subgroup
analysis, in which pre-specified subgroups of the population are assessed for
differential treatment effects, to the point where the treatment benefit for
each individual is used to determine a treatment assignment rule that is, in
some sense, optimal.
Several strategies for identifying treatment rules have been proposed
in the literature. Many of these utilize a model for the conditional mean
function of the outcome given treatment and covariates, and optimize it
over available treatments to define an ITR. Qian and Murphy [15] show
that good prediction accuracy of the outcome model is sufficient in order
to ensure good performance of the associated ITR. As a result a number
of strategies for flexible prediction models have been proposed, including a
large linear aproximation space with penalization to avoid overfitting ([15,
9]), generalized additive models ([14]), boosting ([10]), random forests ([5]),
support vector regression ([24]), kernel ridge regression ([22]), and tree based
methods or recursive partitioning ([4, 3, 13, 18, 20, 11]). An alternative
strategy is to directly optimize an estimator of the expected outcome of a
treatment rule over a class of potential rules ([19, 21, 23, 6]). This has the
advantage of not requiring an accurate prediction model, but does require
specification of the class of treatment rules allowed. While each method
uses its own “optimal” choice, in this article we reserve the phrase “Optimal
ITR” for the ITR defined by Qian and Murphy [15] in their Equation 1, and
also stated in our Equation 1 below.
The Bayesian framework leads to natural quantification of uncertainty
that allows construction of credible and prediction intervals. A major dis-
tinguishing feature as described later is that our method provides direct
inference on the value of the Optimal ITR while it is not clear how this
can be done with other existing methods. The Bayesian nonparametric re-
gression method we have implemented here is Bayesian Additive Regression
Trees (BART) ([2]) to model the conditional mean function of the outcome
and to inform identification of an ITR. BART has been shown to be efficient
and flexible with performance comparable to or better than its non-Bayesian
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competitors such as boosting, lasso, MARS, neural nets and random forests
([2]). Furthermore, our simulations described later in the article show that
BART ITR’s performance was better than or comparable to other existing
methods in this setting of identifying an ITR. Because of its tree based struc-
ture, BART can effectively address interactions among variables, which is
important in this context for identification of treatment interactions leading
to differential treatment recommendations. In addition, recent modifica-
tions to BART have been proposed that maintain excellent out-of-sample
predictive performance even when a large number of additional irrelevant
regressors are added ([12]).
We present our work in the following sequence. In the next section we
describe the notation for individualized treatment rules. Following that, we
review the BART methodology briefly. The next section titled “BART for
ITRs and Value Function Estimation” describes our proposed BART based
ITR and addresses estimation of its value function as well as that of the
Optimal ITR. Subsequently we show excellent performance of the proposed
BART ITR in a benchmark simulation comparison to existing methods for
ITRs. In the next section we conduct additional simulations to examine the
operating characteristics of the BART prediction model and the estimation
of the value function. In the section titled “Summarizing the BART ITR”
we discuss ways to approximate the BART ITR to get an interpretable
clinical rule for treatment assignment, similar to identification of subgroups
of patients who would benefit from assignment to particular treatments.
The following section illustrates the usage of the proposed method on a
medical application in hematopoietic cell transplantation. The article ends
with a discussion of our contribution as well as of some planned future
developments.
2 Individualized Treatment Rules
Let Y be the outcome of interest, with higher values of Y being more desir-
able. We focus on a binary outcome in this article, where Y = 1 indicates
a favorable outcome and Y = 0 its complement, but the proposed method
could easily be used with a continuous outcome as well. Let A be the treat-
ment space with A = {−1, 1} and let X = (x1, . . . , xp) be the vector of
patient characteristics being used to personalize treatment, with population
space ΩX defined so that p(A = 1|X = x) is bounded away from 0 and 1,
i.e. ΩX = {X : p(A = a|X = x) ∈ (0, 1), ∀a ∈ A}. We assume observations
represent a random sample (Y,A,X) either from a randomized trial or obser-
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vational study. For an observational study we make the usual assumptions
to allow causal inference that treatment assignment is strongly ignorable,
i.e. treatment A is independent of the potential outcomes Y |A = 1 and
Y |A = 0 given X. Note that BART models have been proposed for use in
observational studies in [8].
A treatment rule g(X) is a mapping from the covariate space Ωx to
the treatment space A so that patients with covariate value X are assigned
to treatment g(X). Let P be the distribution of (Y,A,X) and E(Y ) be
the expectation with respect to P . Let P g be the distribution of (Y,A,X)
given that A = g(X) and let Eg(Y ) be the expectation with respect to P g.
The value function V (g) of a treatment rule g(X) is the expected outcome
associated with that treatment rule, i.e., V (g) = Eg(Y ). An Optimal ITR
g0 is a treatment rule that optimizes the value function,
g0 ∈ arg maxg∈GV (g),
where G is a collection of possible treatment rules. Since the value function
can be written as
V (g) = E[E(Y |X,A = g(X))],
Qian and Murphy [15] show that the Optimal ITR satisfies
g0(X) ∈ arg maxa∈AE(Y |X,A = a) a.s., (1)
so that one possible solution is to assign to each patient the treatment which
has the higher conditional expectation given their covariate vector X. In
practice, this strategy requires modeling of the conditional mean function
and use of the estimated conditional mean function in the above expression
to determine treatment assignment. Qian and Murphy [15] showed that if
the prediction error of such a model is small, then the reduction in value of
the associated ITR g compared to the Optimal ITR g0 is also small, pointing
to the need for a flexible and accurate prediction model for the conditional
mean function.
3 BART methodology
As BART is based on an ensemble of regression tree models, we begin with
a simple example of a regression tree model. We then describe how BART
uses an ensemble of regression tree models for a numeric outcome. Finally,
we describe how the BART model for a numeric outcome is augmented to
model a binary outcome.
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Figure 1: An example of a single tree with branch decision rules and terminal
nodes
Suppose yi represents the (numeric) outcome for individual i, and xi is
a vector of covariates with the regression relationship yi = h(xi;T,M) +
i. Notationally, h(xi;T,M) is a binary tree function with components
T and M that can be described as follows. T denotes the tree structure
consisting of two sets of nodes, interior and terminal, and a branch decision
rule at each interior node which typically is a binary split based on a single
component of the covariate vector. An example is shown in Figure 1 wherein
interior nodes appear as circles, and terminal nodes as rectangles. The
second tree component M = {µ1, . . . , µb} is made up of the function values
at the terminal nodes.
BART employs an ensemble of such trees in an additive fashion, i.e., it
is the sum of m trees where m is typically large such as 200. The model can
be represented as:
yi = f(xi) + i where i
iid∼ N (0, σ2)
f(xi) =
∑m
j=1 h(xi;Tj ,Mj)
}
. (2)
To proceed with the Bayesian specification we need a prior for f . Notation-
ally, we use
f ∼ BART (3)
and describe it as made up of two components: a prior on the complexity
of each tree, Tj , and a prior on its terminal nodes, Mj |Tj . Using the Smith-
Gelfand bracket notation [7] for distributions, we write [f ] =
∏
j [Tj ] [Mj |Tj ]
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. Following [2], we partition [Tj ] into 3 components: the tree structure or
process by which we build a tree and create interior nodes, the choice of
a covariate given an interior node and the choice of decision rule given a
covariate for an interior node. The probability of a node being interior is
defined by describing the probabilistic process by which a tree is grown. We
start with a tree which is a single node and then recursively let a node have
children (so that it is not a terminal node) with probability α(1+d)−γ where
d represents the branch depth, α ∈ (0, 1) and γ ≥ 0 . We assume that the
choice of a covariate given an interior node and the choice of decision rule
branching value given a covariate for an interior node are both uniform. We
then use the prior [Mj |Tj ] =
∏bj
`=1 [µj`] where bj is the number of terminal
nodes for tree j and µj` ∼ N
(
0, τ2/m
)
on the values of the terminal nodes.
This gives f(x) ∼ N(0, τ2) for any x since the value f(x) will be the sum
of m independent N(0, τ2/m). Along with centering of the outcome, these
default prior mean and variance are specified such that each tree is a “weak
learner” playing only a small part in the ensemble; more details on this can
be found in [2].
To apply the BART model to a binary outcome, we use a probit trans-
formation
p(Y = 1|x) ≡ p(x) = Φ(µ0 + f(x))
where Φ is the standard normal cumulative distribution function and f ∼
BART . To estimate this model we use the approach of Albert and Chib [1]
and augment the model with latent variables Zi:
Yi = IZi≥0
Zi = µ0 + f(xi) + i
f(xi) =
∑m
j=1 h(xi;Tj ,Mj)
f ∼ BART
(4)
where IZ≥0 is one if Z ≥ 0 and zero otherwise and i ∼ N(0, 1). The Albert
and Chib method then gives inference for f using the Gibbs sampler which
draws Z|f and f |Z.
The model just described can be readily estimated using existing soft-
ware for binary BART. It allows one to estimate the functions f(x) through
Markov Chain Monte Carlo draws of f from which draws of the correspond-
ing success probabilities p(x) = Φ(µ0 + f(x)) are readily obtained. Here µ0
is a tuning parameter to be chosen. For example, setting µ0 = 0 centers the
prior for p(x) at .5 since the BART prior for f is centered at 0; however, the
BART model is fairly robust to different prior values of µ0 given sufficient
data. In the binary probit case, we let τ = 1.5. With this choice there is a
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95% prior probability that f(x) is in the interval ±2(1.5) giving a reasonable
range of values for p(x).
4 BART for ITRs and value function estimation
Due to the excellent flexibility in modeling complex interactions and the
strong predictive performance, we propose to use individualized predictions
of patient outcomes from the BART model to determine an ITR. In addi-
tion to constructing an ITR based on BART predictions, we use the BART
MCMC to assess uncertainty about various aspects of the treatment decision
and resulting value function.
In applying BART to the ITR problem, our “x” of the previous sec-
tion (in which we reviewed BART) becomes (x, a) where, as in the section
introducing ITR’s, a is the decision variable and x is patient information.
The BART model implies p(Y = 1|x, a, f) = Φ(µ0 + f(x, a)) where
f is expressed as the sum of trees as in Equation (4). Posterior MCMC
draws {T dj ,Mdj } consist of the individual trees j = 1, 2, . . . ,m, for MCMC
iterations d = 1, 2, . . . , D. Using Equation (4), each of these draws results in
a draw fd of the function f . In this section, it is helpful to view the function
f as the fundamental underlying parameter. BART is viewed as giving us
draws {fd}Dd=1 from the posterior distribution of f .
4.1 Decision Theoretic Predictive BART ITR
From Equation (1), the Optimal ITR is obtained by choosing the value of
a which maximizes E(Y |x, a) = p(Y = 1|x, a) conditional on X = x. In
our Bayesian framework, p(Y = 1|x, a) is the predictive probability that
Y = 1 which is obtained by integrating p(Y = 1|x, a, f) over the posterior
distribution of the parameter f . Given MCMC draws {fd} from the posterior
distribution of f , this integral is approximated by averaging over the draws:
p(Y = 1|x, a) ≈ 1
D
D∑
d=1
p(Y = 1|x, a, fd) ≡ p¯(x, a). (5)
Thus, p¯(x, a) is the MCMC estimate of the predictive p(Y = 1|x, a). Illus-
trations of inference on patient specific predictive probabilities are shown
later in the Example Section and in Figure 5.
We can now define the BART based ITR as the one in which the treat-
ment for each individual is given by maximizing the patient specific predic-
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tive probability over available treatments:
gBART(x) = arg max
a
p¯(x, a). (6)
The construction of gBART follows the basic prescription of Bayesian de-
cision theory in which we pick the action which maximizes expected utility.
In this case, our utility is the outcome Y , and because Y is binary, the ex-
pected Y is the probability that Y = 1, so we simply pick the action which
gives us the highest predictive probability of a successful outcome.
4.2 Posterior Distribution of the Value function of an ITR
For any ITR g(x) it is of interest to assess its value across the patient
population so that different ITRs may be compared via this value. With an
underlying function f , the value of the ITT g is defined as
V (g, f) = EX(p(Y = 1|x, g(x), f),
which is the average (over x) of the probability of a good outcome. Given
MCMC draws we can approximate the marginal distribution of this function
of the uncertain f by simply plugging in draws of f :
Vd(g) = V (g, fd). (7)
The posterior samples {Vd(g)}, d = 1, 2, . . . , D, provide inference for the
value function of any ITR g, including the BART ITR in Equation (6),
approximating the expectation over X by an average over a representative
distribution of x which is often taken to be the observed samples in the
covariate space. Illustrations of inference on the value function can be found
later in the Example Section and in Figure 5.
4.3 Posterior Distribution of the Value function of the Op-
timal ITR
It is also possible to estimate and assess uncertainty of the value associated
with the optimal ITR as defined in Equation (1). We consider the optimal
ITR as a function of f . If we knew f then, given x, the optimal action is
given by
a(x, f) = arg max
a
p(Y = 1|x, a, f)
with corresponding maximum success probability p∗(x, f) = maxa p(Y =
1|x, a, f). Draws of the value of the Optimal ITR, namely V ∗ = EX(p∗(x, f))
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can be obtained from draws of f as
V ∗d = EX(p
∗(x, fd)), d = 1, . . . , D.
Again, the expectation over X is typically an average of representative x
values, often using the observed samples in the covariate space. We can
interpret the draws Vd collectively as representing uncertainty about the
value of the Optimal ITR, i.e., the ITR for an agent who acts knowing the
true f . Illustration of this is also found later in the Example Section and
Figure 5 (c) and (d).
5 Comparison with Existing Methods
We conducted extensive simulation studies benchmarking the proposed BART
ITR strategy against existing methods for identifying ITRs. In order to
avoid any concerns that we are deliberately selecting simulation settings
where BART will show good performance, we reproduced simulation set-
tings from two recent papers ([19, 10]) with a binary outcome variable Y
and binary treatment A. The first set of simulations from [19] included 5
additional binary covariates XA : XE , 5 ordinal covariates Xa : Xe with
4 categories each, and one or two continuous covariates XCa, XCb. Eight
different scenarios for the logit of the probability of response were simulated
according to the following:
(A) 0.5XC1 + 2(XB1 +Xa3 ∗XA1) ∗A
(B) 0.5XC1 + 2(XB1 +Xa3 ∗ (Xb2 +Xb3)) ∗A
(C) 0.05(−XA1 +XB1) + [(Xa2 +Xa3) + (Xb2 +Xb3) ∗XCa] ∗A
(D) log log[(Xb3 +Xc3) + 5(Xa2 +Xa3 +XA1XB1) ∗A+ 20]2
(E) (XA1 +XB1) + 2 ∗A
(F) 0.5XA1 + 0.5XB1 + 2I(XCa < 5, Xa < 2) ∗A
(G) 0.5XA1 + 0.5XB1 + 2I(XCa < 5, XCb < 2) ∗A
(H) 0.5XCa + 0.5XCb + 2I(XCa < −2, XCb > 2) ∗A
We also considered a modification of these scenarios (denoted (A2-H2)) in
which the treatment interaction term was reduced to 1/4th of the given
value, in order to better differentiate among the competing methods. In the
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second set of simulations from [10], up to 3 independent continuous markers
X1, X2, X3 were included in seven different models for the probability of
nonresponse according to the following:
(K1) logitp(Y = 0|A,X) = 0.3 + 0.2X1 − 0.2X2 − 0.2X3 +A(−0.1− 2X1 −
0.7X2 − 0.1X3), Xj ∼ N(0, 1)
(K2) logitp(Y = 0|A,X) = 0.3 + 0.2X1 − 0.2X2 − 0.2X3 +A(−0.1− 2X1 −
0.7X2 − 0.1X3), Xj ∼ N(0, 1) except for 2% of high leverage points
with X1 ∼ Uniform(8, 9).
(K3) log(− log p(Y = 0|A,X)) = −0.7 − 0.2X1 − 0.2X2 + 0.1X3 + A(0.1 +
2X1 −X2 − 0.3X3), Xj ∼ N(0, 1)
(K4) log(− log p(Y = 0|A,X)) = 2 − 1.5X21 − 1.5X22 + 3X1X2 + A(−0.1 −
X1 +X2), Xj ∼ Uniform(−1.5, 1.5)
(K5) logitp(Y = 0|A,X) = −0.1− 0.2X1 + 0.2X2− 0.1X3 +X21 +A(−0.5−
2X1 −X2 − 0.1X3 + 2X21 ), Xj ∼ N(0, 1)
(K6) logitp(Y = 0|A,X) = 0.1 − 0.2X1 + 0.2X2 −X1X2 + A(−0.5 −X1 +
X2 + 3X1X2), Xj ∼ N(0, 1)
(K7) p(Y = 0|A,X) = I(X1 < 8)(1 + e−η)−1 + I(X1 ≥ 8)(1− (1 + e−η)−1),
where η = 0.3+0.2X1−0.2X2−0.2X3+A(−0.1−2X1−0.7X2−0.1X3)
and Xj ∼ N(0, 1) except for 2% of high leverage points with X1 ∼
Uniform(8, 9).
In all cases, ITRs were generated using a training dataset with n = 500
observations, and then each ITR was applied to a fixed independent test
dataset of 2000 observations in order to compute the value function for this
ITR from the true model. This process was replicated using 50 training
datasets, and the average value function across the 50 training sets was
obtained. This average value function for a particular ITR was normalized
as a fraction of the true optimal value function to facilitate comparisons
across scenarios.
For the BART ITR, we considered both use of the default prior pa-
rameters (BARTd), as well as cross-validation to select the number of trees
(m=80,200) and a divisor for the prior SD τ , denoted k = (0.1, 0.4, 1.0) with
default value of 1 (BARTcv). Several competing methods were included for
comparison, including regularized outcome weighted subgroup identification
(ROWSI) ([19]), Outcome Weighted Learning (OWL) ([23]), use of random
forests (RF) for outcome prediction along the lines of virtual twins approach
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([5]) with cross validation of number of trees and minimum node size, and
boosting with classification tree working model (KANG) ([10]). Ordinal
variables were handled as ordinal for BART and other tree based methods,
but were otherwise treated as categorical variables.
Results are shown in Figure 2. In all cases, the value function of the
BART ITR with cross-validation performed at or near the top of the com-
peting methods. BART with the default settings also performed comparably
to the other existing methods, with good performance in most situations.
6 Illustration of Operating Characteristics of BART
prediction models and Estimation of Optimal
Value Function
We demonstrate the features of the proposed method using generated data
from two settings: a complex treatment interaction setting, and a main
effect only setting. In each case, training datasets of either n = 500 or
n = 5000 were generated and applied to an independent test dataset of
2000 observations. Logistic regression with a binary outcome and three
independent Uniform(−1.5, 1.5) covariates was used to generate the data,
with a complex treatment interaction model according to
P (Y = 1|A,X) = [1 + exp{−0.1− 0.2X1 + 0.2X2 − 0.1X3 + 0.5X21
+A(−0.5− 0.5X1 −X2 − 0.3I(X3 > 0.5) + 0.5X21 )
}]−1
.
and a no treatment interaction model according to
P (Y = 1|A,X) = [1 + exp{−0.1− 0.2X1 + 0.2X2 − 0.1X3 + 0.5X21 − 0.3A}]−1 .
In Figure 3 we plot the BART posterior means vs. the true probabilities
of treatment outcome for the test dataset, for each treatment as well as
for the treatment difference, for single training datasets of size n = 500
((a),(c),(e)) and n = 5000 ((b),(d),(f)) using the complex interaction model.
The posterior mean prediction from the BART model has excellent accuracy
for the large sample size, both for individual treatment outcomes as well
as for the treatment difference, despite the complex treatment interaction
model which includes linear and quadratic covariate-treatment interactions
as well as an interaction term with a thresholded value of a covariate. The
larger training dataset shows improved accuracy compared to the smaller
training dataset, which has some modest shrinkage of the treatment effects.
11
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Figure 2: Value function relative to the optimal value function for simulation
settings in (a) scenarios as in [19], (b) same as (a) but with treatment effects
cut by 25%, and (c) scenarios as in [10]
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We also conducted repeated data simulations with 400 replicates to look
at the bias of the prediction model as well as coverage of the 95% interval
estimates for the value function of the Optimal ITR, using the quantiles of
the posterior samples for the value function of the Optimal ITR. Bias over
400 replicates for the treatment difference is shown in Figure 3, panels (g)
and (h). As is seen with the single training dataset, there is some small
bias and shrinkage of the treatment effects for smaller sample size which
disappears with larger sample size. Coverage probabilities of 95% credible
intervals for the value of the Optimal ITR are 90% for training dataset of
size n = 500 and 95% for training dataset of size n = 5000, indicating that
once the sample size is sufficient to reduce the shrinkage of the treatment
effects, coverage of the value function for the Optimal ITR is excellent.
Similar results are shown for the model with no treatment-covariate in-
teraction in Figure 4. Note that the true treatment differences show very
narrow variability due to the data generating model, and the BART model
shows predictions for treatment differences which are also small and which
narrow with increasing sample size. These predictions are unbiased in re-
peated simulation, as indicated by the convergence to the diagonal line in
Figure 4 panels (c) and (d).
7 Summarizing the BART ITR
The ITR based on the BART prediction model does not directly yield a
simple interpretable rule; this issue in general with flexible models has been
discussed in [22], who propose directly optimizing the value function over
an interpretable set of rules. In contrast, we separate the modeling of out-
come from the determination of an interpretable rule, by trying to develop
an approximation to this BART ITR which is interpretable and yields good
performance. We propose a “Fit-the-fit” strategy, in which one develops
a single tree fit to the posterior mean treatment differences as a function
of patient characteristics. Essentially, the posterior mean treatment differ-
ences are treated as the “data”, and we try and fit an interpretable single
tree to this data. The single tree then provides an interpretable way to ex-
plain which groups of patients should receive which treatment, as well as the
magnitude of the treatment difference for that group of patients. This strat-
egy was originally proposed as a variable selection technique for a BART
prediction model, but has been adapted here to focus on summarizing the
inference on treatment differences and the BART ITR.
13
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
ll
l
l
l
l l
l l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l l
l
l
l
ll
l
l
l
l
ll
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l l
l
l
l
l l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
ll l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
ll
l
l l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
True outcome for treatment 1
Po
st
er
io
r m
ea
n 
fo
r 
tr
t. 
1 (a)
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l lll
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
ll l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
ll
l
l
l
l
l
l
l
l l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
True outcome for treatment 1
Po
st
er
io
r m
ea
n 
fo
r 
tr
t. 
1 (b)
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
lll
lll
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l l
l
l
l
l
l
l
l l ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
ll l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
ll
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l ll
l
ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l ll
l
l
l
l
l
l
l
l l
l
l
l l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
ll l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l l
l
l l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
True outcome for treatment 0
Po
st
er
io
r m
ea
n 
fo
r 
tr
t. 
0 (c)
l
l
l
l
l
l
l
l
l
l l
l
l
l l
l
l
lll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
ll l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l lll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l ll
l
l
ll
l
l
l
l
l
l
l
ll
l
l
ll
l
l
ll l
l
l
l
l
ll
ll
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l l
l
l
l
l
l
l
l
l l l
l l
ll
l
l
l
l
l
l
ll l
l
l
l
l
l
l
l
ll
l
l
l l
l
l
ll
l
l l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l l
l
l
l
l l
l l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l ll
l l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l ll
l
l
l
ll
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
ll
l
l
l
0.00
0.25
0.50
0.75
1.00
0.00 0.25 0.50 0.75 1.00
True outcome for treatment 0
Po
st
er
io
r m
ea
n 
fo
r 
tr
t. 
0 (d)
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l l l
ll
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l
l
l
l
l
l
l
l
l l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
ll l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
ll
l
l
l
l
l l
l
l l
l
l
llll
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l l
l
l
lll
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
−0.50
−0.25
0.00
0.25
0.50
−0.50 −0.25 0.00 0.25 0.50
True treatment difference
Po
st
er
io
r m
ea
n 
tr
t. 
di
ff.
(e)
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l l l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l l
l
l
l
l
ll
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
−0.50
−0.25
0.00
0.25
0.50
−0.50 −0.25 0.00 0.25 0.50
True treatment difference
Po
st
er
io
r m
ea
n 
tr
t. 
di
ff.
(f)
l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l l
l
ll
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l l
l l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l l
l l
l
l
l
ll
l
l
l
l
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l l
ll
l
l l
l
l
l
l
l
l
l
l
ll
l
l l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
ll
l
l
l l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l l
−0.50
−0.25
0.00
0.25
0.50
−0.50 −0.25 0.00 0.25 0.50
True treatment difference
Po
st
er
io
r m
ea
n 
tr
t. 
di
ff.
(g)
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l l
l l
l
l
l
l
l
l
l
l
l
l l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l l
l
l
l
l l
−0.50
−0.25
0.00
0.25
0.50
−0.50 −0.25 0.00 0.25 0.50
True treatment difference
Po
st
er
io
r m
ea
n 
tr
t. 
di
ff.
(h)
Figure 3: BART posterior means vs. true probabilities for complex inter-
action model, with n = 500 (left side) and n = 5000 (right side). First two
rows show predictions for individual treatment outcomes, while row 3 shows
predictions for treatment differences, all using a single training dataset. Row
4 shows the posterior means for the treatment difference averaged over 400
repeated data simulations of the training set.
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Figure 4: BART posterior means vs. true probabilities for no interaction
model, with n = 500 (left side) and n = 5000 (right side). First row shows
predictions for treatment differences using a single training dataset, while
row 2 shows the posterior means for the treatment difference averaged over
400 repeated data simulations of the training set.
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To fit an appropriate tree and also identify the best set of variables to
include in that tree, a sequence of trees are fit, where variables are sequen-
tially added to the candidate set of splitting variables in a stepwise manner
to improve the fit. Given a current set of variables and a corresponding tree
built using those variables, the fit of the current tree is assessed using the
R2 between the fitted values from the tree and the posterior mean treat-
ment difference (which is being used as the “data”). Additional variables
are considered to be added one at a time yielding new trees built with an
increasing set of variables, and their R2 is assessed for each new variable
added and corresponding tree. The variable which most increases the R2
is selected at each step. Once the R2 does not improve appreciably with
addition of a new variable (we used ∆R2 < 1%), the procedure ends and
the current tree is used as the approximation to the BART ITR.
Note that each single tree fit can be implemented very quickly, so this fit
the fit postprocessing procedure takes minimal computing time. It may not
always be possible to identify such a single tree (this is in fact the benefit
of ensemble methods to provide improved prediction), but note that the
quality of such an interpretable approximation can be assessed using the R2
between the single tree and the BART prediction model. It is also possible
to compute the value function of the single-tree approximation ITR, and
compare it with that of the full BART-ITR.
8 Example
We illustrate the proposed methodology with a study of 1 year survival out-
comes after a hematopoietic cell transplant (HCT) used to treat a variety
of hematologic malignancies. We use data on 3802 patients receiving re-
duced intensity conditioning for their HCT between 2011-2013, with data
reported to the Center for International Blood and Marrow Transplant Re-
search (CIBMTR). Follow up to 1 year is complete for all patients so we
analyze the outcomes using binary methods as described throughout the
paper applied to the patient’s survival status at 1 year. Note that a full
survival analysis could also be conducted with BART methods available
for survival data([17]), however this requires consideration of the appropri-
ate target outcome to optimize and so we defer this for future research.
The primary treatment of interest is the type of conditioning regimen used
(Fludarabine/Melphalan, or FluMel for short, vs. Fludarabine/Busulfan,
or FluBu for short). A variety of patient, donor, and disease factors were
examined for their utility in personalizing the selection of the conditioning
16
regimen, including age, race/ethnicity, performance score, Cytomegalovirus
status, disease, remission status, disease subtypes, chemosensitivity, interval
from diagnosis to transplant, donor type, Human Leukocyte Antigen (HLA)
matching between donor and recipient, prior autologous transplant, gender
matching between donor and recipient, comorbidity score, and year of trans-
plant. This observational cohort appears to be well balanced between the
regimens across these factors, indicating reasonable equipoise by clinicians
on which conditioning regimen is most appropriate for individual patients.
Fitting of the BART model provides samples from p(Y = 1|x, a, fd) for
d = 1, . . . , D. In Figure 5 we show waterfall plots of the differences in 1
year survival between Flu/Mel and Flu/Bu conditioning across patients in
two ways. In (a) we use the samples from the patient specific difference in
1 year survival, p(Y = 1|x, a = Flu/Mel, fd) − (Y = 1|x, a = Flu/Bu, fd),
and plot the posterior mean of these differences in 1 year survival for each
patient, sorted by the magnitude of the difference. This is equivalent to
the difference in predictive probabilities under each treatment condition as
described in Equation 5. Inter-quartile ranges and 95% posterior intervals
are also shown to indicate the variability of the differences. In (b) we show
the waterfall plot of the posterior probabilities that Flu/Mel has a higher 1
year survival than Flu/Bu. This is obtained by computing
1
D
∑
d
I(P (Y = 1|x, a = Flu/Mel, fd) > P (Y = 1|x, a = Flu/Bu, fd)).
These plots indicate some heterogeneity in treatment benefit, where approx-
imately 3000 of the patients seem to benefit from Flu/Mel, albeit with vary-
ing degrees of magnitude and/or certainty surrounding that benefit, while
the remaining patients seem to benefit from Flu/Bu conditioning.
Also in Figure 5 (c) we show the value functions as described in Equa-
tion 7 for the cohort of n = 3802 patients for three treatment rules: all
patients receive Flu/Bu, all patients receive Flu/Mel, and patients receive
treatment according to the BART based ITR. The BART ITR value func-
tion distribution is shifted to the right, indicating improved 1 year survival
outcomes over the overall cohort using this individualized strategy. The pos-
terior mean of the value function distributions for each treatment strategy
are: FluBu: 0.651, FluMel: 0.667, BART ITR: 0.677, Optimal ITR: 0.682.
Figure 5 (d) shows the density functions of the difference in value function
for the BART ITR compared to the other strategies, indicating high like-
lihood that the BART ITR is superior to the fixed treatment strategies.
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Figure 5: Results of BART ITR for HCT example. (a) Waterfall plot of 1 yr
survival differences (FluMel-FluBu) by patient (posterior mean differences,
along with inter-quartile ranges and 95% posterior intervals), (b) Waterfall
plot of posterior probabilities that survival is higher for Flu/Mel, (c) Density
plot of value functions for three treatment strategies (FluMel, FluBu, BART
ITR) as well as Optimal ITR, and (d) Density plot of difference in value
functions for treatment strategies compared to BART ITR. The posterior
mean of the value function distributions for each treatment strategy are:
FluBu: 0.651, FluMel: 0.667, BART ITR: 0.677, Optimal ITR: 0.682.18
On the other hand, it is inferior to the Optimal ITR as expected, but the
differences are small.
As pointed out earlier, one drawback of the BART based ITR is that
it does not lead to a simple interpretable rule. Next we apply the fit the
fit technique to approximate the BART based ITR with an interpretable
treatment rule which has nearly as good performance. In order to do this,
the posterior mean treatment differences in 1 year survival are treated as the
“data”, and we try and fit an interpretable single tree to this data. In order
to do this, a sequence of trees are fit, where variables are added sequentially
to the set of potential splitting variables of the tree in a stepwise manner to
improve the fit. Once the change in R2 is less than 1% with addition of a new
variable, the procedure ends and the current tree is used as the approxima-
tion to the BART ITR. The results of the final tree fit are shown in Figure 6;
R2 between the tree fit and the posterior mean treatment differences is 97%.
The first splitting variable used, Non-Hodgkins Lymphoma (NHL) disease
vs. other disease, was sufficient to match the BART ITR exactly in terms
of selection of conditioning regimen; Patients with NHL have approximately
5% better 1 year OS with Flu/Bu conditioning, while patients without NHL
have approximately 3% better 1 year OS with Flu/Mel conditioning. A sec-
ond level of splitting variables provided further resolution on the magnitude
of the treatment benefit for disease subgroups, but did not affect the direc-
tional benefit. Patients with AML have approximately 5% better 1 year OS
with Flu/Mel conditioning, while patients with other diseases have approx-
imately 1% better 1 year OS with Flu/Mel conditioning. Similarly, among
patients with NHL disease, those with aggressive B-cell subtype may experi-
ence slightly more benefit from Flu/Bu conditioning compared to those with
other subtypes (7% vs. 5%). Note that in this case, this simple rule com-
pletely matched the BART based ITR, and so the value function associated
with this rule also matches the BART ITR value function in the previous
figure. This type of approximation to a BART based ITR can greatly facil-
itate communication with clinicians on how the ITR works and what types
of patients benefit from one treatment vs. another.
9 Discussion
In this article, we presented a framework for identifying optimal individu-
alized treatment rules using Bayesian Additive Regression Trees. BART is
a flexible fully nonparametric prediction model which can handle complex
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Figure 6: Tree fit to the posterior mean treatment differences. Values in each
node represent the posterior mean and 95% credible intervals for the average
treatment effect of the subgroup of patients represented in that node.
functional forms as well as interactions among variables, and therefore it is
well suited for examining treatment interactions which drive ITRs. There
are two main advantages to using BART to identify an ITR. First, our
proposed method has excellent performance when benchmarked against ex-
isting methods, including other flexible prediction methods as well as policy
search methods such as outcome weighted learning; overall it performed
better than or comparable to other existing methods across a range of ITR
simulation settings established in other papers. Second, our method pro-
vides direct inference on the value of the BART ITR as well as the Optimal
ITR. This requires incorporation of both the uncertainty in the prediction
model, as well as uncertainty in the individual patient treatment selection
that depends on the prediction model. Both can be handled in a straightfor-
ward manner using the posterior samples for the prediction model function
in the Bayesian framework. In contrast, it is not clear how to do this for
policy search methods which do not provide a direct prediction model for
outcome, as well as for other flexible models such as random forests which
do not directly provide uncertainty measures.
We observed that the BART model tends to shrink the treatment effect
estimates for smaller sample size leading to underestimation of the true value
of the Optimal ITR. Larger sample sizes do overcome this shrinkage from
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the prior. Further consideration of ways to reduce this unidirectional bias
could provide better inference on the value function for small sample sizes.
One limitation of our proposed method is that the BART method gener-
ates a “black box” prediction model which is difficult to explain to clinicians.
However, we showed how the posterior mean differences available from the
model can be fed into a tree procedure to yield an interpretable ITR which
provides a close approximation to the BART ITR and which can be readily
explained to clinicians. A recent article [16] describes the use of BART and
utility specifications with the goal of identifying subgroups with elevated
treatment effects, in contrast to finding an individualized treatment rule.
Our proposed method uses “off-the-shelf” BART software; minimal pro-
cessing is needed to obtain posterior inference under each treatment con-
dition for patients in a test dataset. Inference for the value of an ITR is
also readily available. While BART can be computationally demanding as
a Markov Chain Monte Carlo (MCMC) technique, it can be parallelized to
save computational time since the chains do not share information beyond
the data itself.
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